Vivos Therapeutics, Inc.VVOSNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +16.93% | +13.85% | -11.79% | -5.77% | +75.73% |
| Gross Profit Growth | +22.97% | +17.22% | -22.10% | -20.41% | +68.68% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +452.54% | +221.15% | +272.39% | +181.48% | +65.73% |
| Weighted Average Shares Diluted Growth | +452.54% | +221.15% | +272.39% | +181.48% | +65.73% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +99.12% | +112.87% | +36.76% | +313.42% | +370.04% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +48.75% | +42.44% | -4.42% | +64.33% | +67.09% |
| Book Value per Share Growth | +2915.72% | +502.61% | +103.34% | -74.35% | -80.07% |
| Debt Growth | -21.91% | -24.21% | -25.66% | +556.52% | +660.68% |
| R&D Expense Growth | -100.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -7.71% | -21.64% | -5.85% | +50.14% | +71.47% |